Vanguard Group
PETX

Vanguard Group’s Aratana Therapeutics, Inc. PETX Stock Holding History

Vanguard Group’s Portfolio PETX Stock Details PETX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-1,341,398
Closed -$6.92M – 4209
2019
Q2 		$6.92M Sell
1,341,398
-1,102,226
-45% -$4.95M ﹤0.01% 3057
2019
Q1 		$8.8M Buy
2,443,624
+164,294
+7% +$712K ﹤0.01% 2894
2018
Q4 		$14M Buy
2,279,330
+235,122
+12% +$1.43M ﹤0.01% 2605
2018
Q3 		$11.9M Buy
2,044,208
+75,166
+4% +$376K ﹤0.01% 2831
2018
Q2 		$8.37M Buy
1,969,042
+105,563
+6% +$532K ﹤0.01% 2990
2018
Q1 		$8.22M Buy
1,863,479
+58,457
+3% +$261K ﹤0.01% 2924
2017
Q4 		$9.49M Buy
1,805,022
+61,605
+4% +$377K ﹤0.01% 2845
2017
Q3 		$10.7M Sell
1,743,417
-177,173
-9% -$1.12M ﹤0.01% 2775
2017
Q2 		$13.9M Sell
1,920,590
-5,964
-0.3% -$36.7K ﹤0.01% 2621
2017
Q1 		$10.2M Buy
1,926,554
+235,208
+14% +$1.59M ﹤0.01% 2763
2016
Q4 		$12.1M Buy
1,691,346
+182,382
+12% +$1.47M ﹤0.01% 2656
2016
Q3 		$14.1M Buy
1,508,964
+238,309
+19% +$1.98M ﹤0.01% 2524
2016
Q2 		$8.03M Buy
1,270,655
+214,900
+20% +$1.38M ﹤0.01% 2752
2016
Q1 		$5.83M Sell
1,055,755
-26,466
-2% -$99.5K ﹤0.01% 2887
2015
Q4 		$6.04M Buy
1,082,221
+8,916
+0.8% +$58.9K ﹤0.01% 2902
2015
Q3 		$9.08M Buy
1,073,305
+95,757
+10% +$1.62M ﹤0.01% 2654
2015
Q2 		$14.8M Buy
977,548
+17,380
+2% +$251K ﹤0.01% 2485
2015
Q1 		$15.4M Buy
960,168
+120,558
+14% +$2.14M ﹤0.01% 2440
2014
Q4 		$15M Buy
839,610
+108,605
+15% +$1.35M ﹤0.01% 2372
2014
Q3 		$7.34M Buy
731,005
+179,704
+33% +$2.18M ﹤0.01% 2639
2014
Q2 		$8.61M Buy
551,301
+55,936
+11% +$793K ﹤0.01% 2570
2014
Q1 		$9.2M Buy
495,365
+384,717
+348% +$7.71M ﹤0.01% 2536
2013
Q4 		$2.11M Buy
110,648
+43,736
+65% +$888K ﹤0.01% 3165
2013
Q3 		$1.09M Buy
+66,912
New +$703K ﹤0.01% 3337

Other funds holding PETX

DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
ASN
Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return

Vanguard Group's PETX Position: Q3 2019 in Review

Vanguard Group sold out of Aratana Therapeutics, Inc. (PETX) in Q3 2019, closing a stake of 1,341,398 shares — an estimated $6.92M sold.

Vanguard Group first reported a position in PETX in Q3 2013 and held it in 24 quarters. The position peaked at $15.4M in Q1 2015. 2 funds tracked by Wall St. Rank hold PETX as of Q3 2019.

  • Vanguard Group reported no remaining Aratana Therapeutics, Inc. position as of Q3 2019 after selling out during the quarter.
  • Vanguard Group sold 1,341,398 Aratana Therapeutics, Inc. shares in Q3 2019, an estimated $6.92M.
  • Vanguard Group first reported a position in Aratana Therapeutics, Inc. in Q3 2013 and held it in 24 quarters.
  • Vanguard Group's Aratana Therapeutics, Inc. position peaked at $15.4M in Q1 2015.
  • 2 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q3 2019.

Based on Vanguard Group's 13F filing for Q3 2019, filed 14 Nov 2019.